Please try another search
GenSight Biologics S.A. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was EUR 3 million compared to EUR 4.9 million a year ago. Net loss was EUR 26.2 million compared to EUR 27.6 million a year ago. Basic loss per share from continuing operations was EUR 0.54 compared to EUR 0.6 a year ago.
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Revenue | 0.142 | 0.142 | 1.36 | 1.36 |
Gross Profit | 0.142 | 0.142 | 1.36 | 1.36 |
Operating Income | -6.3 | -6.3 | -8.55 | -8.55 |
Net Income | -7.13 | -7.13 | -5.98 | -5.98 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Assets | 16.73 | 16.73 | ||
Total Liabilities | 43.8 | 43.8 | ||
Total Equity | -30.7 | -27.07 | -27.07 | -27.07 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | -4.25 | -4.25 | -8.1 | -8.1 |
Cash From Investing Activities | 0.028 | 0.024 | 0.076 | 0.076 |
Cash From Financing Activities | 4.75 | 4.75 | 3.2 | 3.2 |
Net Change in Cash | 0.494 | 0.556 | -4.79 | -4.79 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review